# KEYNOTE 050 (NCT02511184)

> Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

No report yet. It can be ordered.

- Drugs tested: crizotinib plus pembrolizumab
- Indication: untreated ALK-positive advanced non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02511184
- Phase: PHASE1
- Status: TERMINATED
- Sponsor: Pfizer
- Conditions: ALK-positive Advanced NSCLC
- Interventions: Crizotinib; Pembrolizumab
- Enrollment: 9
- Primary outcome: Number of Participants With Dose-limiting Toxicity (DLT)

## Indexed commentary on KEYNOTE 050 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=keynote-050-nct02511184
